Understanding the Impact of Delta Variant and Breakthrough Infections
Learn about the characteristics of the Delta variant, its increased transmissibility, and the emergence of breakthrough COVID-19 cases post-vaccination. Explore the testing needs and gap analysis in managing the ongoing pandemic situation.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
B.1.617.2 (Delta) variant Approximately 3-fold more transmissible Dominant variant nationwide People who are infected with the delta variant have more copies of the virus in their respiratory tracts than those infected with the original strain. There is also evidence that people who are infected can transmit the virus earlier in the course of their illness and before they are symptomatic and aware of the infection. 2
OHA Breakthrough infection report 8/19 Vaccine breakthrough cases are defined as instances in which an individual tested positive for COVID-19 at least 14 days following the completion of any COVID-19 vaccine series. Vaccine breakthrough cases that result in hospitalization or death are reported to CDC During the weeks of August 1-14, there were 20,701 cases of COVID-19. 17,719 (85.6%) were unvaccinated and 2982 (14.4%) were vaccine breakthrough cases. The median age of breakthrough cases was 46 years. 95 breakthrough cases were residents of care facilities, senior living communities, or other congregate living settings. 664 (22.3%) of cases were 65 or older. There were 52 (1.7%) cases aged 12-17. To date, 5.8% of all known breakthrough cases have been hospitalized (n=413), and only 0.8% have died (n=58). The median age of the people who died was 82 (range: 49-101).
Testing needs and gap analysis The amount of COVID-19 in the community, surveillance and screening testing all determine testing needs As of August 1, we estimate that Oregon needed approximately 48K tests/day Corresponding estimated testing volume: 20K tests/day We have seen testing capacity increase to 32K tests/day in the past We are receiving increasing reports of testing supply chain issues Additional demands on testing capacity include: K-12 screening: 10% participation = 58K tests/week GO mandate for unvaccinated HCWs = up to 85K tests/week Non-supply issues remain Healthcare workforce shortages Reallocation of resources from testing to vaccines Testing acceptance Testing access 10
COVID-19 Vaccine Doses Administered per Day Source: OHA public tableau site
7-day running average doses administered and people initiated - all ages (data from ALERT IIS through 8-12-21) View dose administrations online here and here View averages of people initiated online here
